Prof. Mikaël Pittet, holder of the ISREC Foundation’s Immuno-Oncology Chair, is this year’s recipient of the Prix du Rayonnement Académique, awarded by the Société Académique Vaudoise.
This prestigious honor recognizes Prof. Pittet’s outstanding scientific contributions. The ISREC Foundation is proud to support this eminent immunotherapy specialist’s research.
Congratulations are in order for Prof. Johanna Joyce of the University of Lausanne, who, together with Roeltje Maas, has published a study in the prestigious journal Cell Press.
This study offers a first description of how the brain tumor environment acts on certain cells, so called neutrophils, to convert them into cells that prevent our immune system from fighting against cancer.
The ISREC Foundation is very pleased to have been able to contribute to this promising research.
For more information The local microenvironment drives activation of neutrophils in human brain tumors: Cell
Félicitations au laboratoire du Dr Grégory Verdeil pour la publication dans la prestigieuse revue Nature Immunology de son étude sur le facteur de transcription NFAT5 qui régule l’épuisement des lymphocytes T dans le contexte du cancer mais pas lors d’une infection virale chronique.
Lien vers la publication (en anglais): Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion | Nature Immunology
Once again, the SUR-SRP “Summer Research” program (July 3 to August 25), organized by the UNIL and the EPFL and supported by the ISREC Foundation, was a huge success. The students were thrilled to discover AGORA. We hope that this once-in-a-lifetime experience will open up new horizons for them.
This year, six research groups working in Lausanne, Geneva, Bern and Bellinzona were awarded a TANDEM grant.
Each team, consisting of a clinician and a basic research scientist, will address a question of direct clinical relevance from two angles: that of understanding the molecular mechanisms involved and that of directly improving cancer patient care.
Congratulations to Prof. Mikaël Pittet, holder of the ISREC Foundation’s Immuno-Oncology Chair at the University of Geneva: in an article published in the prestigious magazine Science, he describes how the expression of two key genes plays a crucial role in cancer progression.
Link to the scientific article
The ISREC Foundation and Two Private Foundations Based in Lausanne Finance a Pioneering Clinical Trial for Leukemia at the CHUV.
In an innovative collaborative approach, the ISREC Foundation is managing the funding of a clinical immunotherapy trial to be conducted at the CHUV. This project, which aims to develop a treatment for children and adults with acute leukemia, is funded through 2.8 million CHF in donations. Thanks to this collaboration, two private foundations can join forces to support translational cancer research and ensure professional scientific monitoring.
See our Annual Report 2022 !
As our 60th anniversary approaches, we are more than ever devoting all our energy to the fight against cancer.
Your support offers scientists and physicians the means to progress faster and further in the battle against this disease.
Thank you from the bottom of our hearts!
In their study, Johanna Joyce and Vladimir Wischnewski (both of the University of Lausanne) were able to show that patients with metastatic brain cancer respond more efficiently to immune checkpoint blockade therapies than patients suffering from primary brain tumors such as gliomas. The scientists analyzed T cells from individuals with primary or metastatic brain tumors as well as from lung and breast cancer patients. In doing so, they were able to identify a subgroup of individuals with brain metastases, mostly of pulmonary origin, but not gliomas, whose tumors presented significant infiltration of potentially tumor-reactive T cells. Additionally, these cells expressed markers indicative of a response to immune checkpoint blockade therapies. These results may serve to efficiently determine which brain tumor patients can benefit from immunotherapy.
The ISREC Foundation is proud to have contributed to this study.